Security Snapshot

KIORA PHARMACEUTICALS, INC. - Common Stock, $0.01 par value (KPRX) Institutional Ownership

CUSIP: 49721T507

13F Institutional Holders and Ownership History from Q2 2024 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

22

Shares (Excl. Options)

1.11MFull value: 1,105,562 · shares · 30 Jun 2026

Price

$2.63

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock, $0.01 par value
Symbol
KPRX on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
1,105,562
Latest holder snapshot 5 signals
Total 13F value
$2,907,476
Portfolio coverage rank
0%
Share change
+766,359
Value change
+$2,041,251
Number of holders
22
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
4,439,655
SEC-reported price per share
$2.53
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • KPRX - KIORA PHARMACEUTICALS, INC. - Common Stock, $0.01 par value is tracked under CUSIP 49721T507.
  • 22 institutions reported positions in Q2 2026.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 18 to 22 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $654.66KFull value: $654,660 · USD · 31 Mar 2026
    to
    $2.91MFull value: $2,907,476 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 22 institutions filings for Q2 2026.

Open SEC evidence

Security key

49721T507

13F reference period

Q2 2026

13F holders

22

13D/G owners

8

CIK / CUSIP context first

Open Q2 2026 holders KPRX full holder history KIORA PHARMACEUTICALS INC SEC filings KIORA PHARMACEUTICALS INC company facts KIORA PHARMACEUTICALS INC insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
8
Security
KPRX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Nantahala Capital Management, LLC 10% 0% $1,293,619 +$140,489 491,889 +12% Nantahala Capital Management, LLC 30 Jun 2026
ADAR1 Capital Management, LLC 9.9% 0% $1,250,197 +$289,812 475,378 +30% ADAR1 Capital Management GP, LLC 30 Jun 2026
PERCEPTIVE ADVISORS LLC 10% $1,163,434 442,387 Perceptive Advisors LLC 06 Apr 2026
Alyeska Investment Group, L.P. 10% +250% $852,483 +$689,126 394,668 +422% Alyeska Investment Group, L.P. 31 Mar 2026
Baselake Partners, LP 5.8% $677,225 257,500 Baselake Partners, LP 10 Sep 2026
HIRSCHMAN ORIN 4.9% -40% $380,178 -$123,265 192,984 -24% Orin Hirschman 31 Dec 2025
Nantahala Capital Partners Limited Partnership 3.4% -38% $321,270 -$88,493 148,736 -22% NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP 31 Mar 2026
GOLDMAN SACHS GROUP INC 0% $429 130 THE GOLDMAN SACHS GROUP, INC. 31 Dec 2024
As of 30 Jun 2026, 22 institutional investors reported holding
1.11MFull value: 1,105,562 · shares · 30 Jun 2026
shares of KIORA PHARMACEUTICALS, INC. - Common Stock, $0.01 par value (KPRX). This represents 25% of the company’s total
4.44MFull value: 4,439,655 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
25%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
PERCEPTIVE ADVISORS LLC 9.9% 438,471 0.02% $1,153,179
ADAR1 Capital Management, LLC 3.8% 167,941 0% 0.02% $441,685
CITADEL ADVISORS LLC 2.6% 116,011 +134% 0% $305,109
TWO SIGMA INVESTMENTS, LP 2% 88,792 0% $233,523
MILLENNIUM MANAGEMENT LLC 1.7% 74,202 0% $195,151
HRT FINANCIAL LP 1.3% 58,612 0% $154,000
RENAISSANCE TECHNOLOGIES LLC 0.67% 29,824 0% $78,437
GEODE CAPITAL MANAGEMENT, LLC 0.6% 26,717 -44% 0% $70,264
VANGUARD CAPITAL MANAGEMENT LLC 0.45% 19,861 0% 0% $52,234
Scientech Research LLC 0.42% 18,746 0.04% $49,302
VANGUARD FIDUCIARY TRUST CO 0.29% 13,030 0% 0% $34,269
LPL Financial LLC 0.28% 12,500 0% $32,875
DIMENSIONAL FUND ADVISORS LP 0.27% 12,138 0% $31,923
NORTHERN TRUST CORP 0.27% 11,767 0% $30,947
JANE STREET GROUP, LLC 0.24% 10,615 0% $27,918
UBS Group AG 0.04% 1,961 +51% 0% $5,157
Caitong International Asset Management Co., Ltd 0.04% 1,813 +30117% 0% $4,768
MORGAN STANLEY 0.03% 1,408 0% 0% $3,703
Tower Research Capital LLC (TRC) 0.02% 837 -16% 0% $2,201
SBI Securities Co., Ltd. 0.01% 256 0% 0% $673
BlackRock, Inc. 0% 58 0% 0% $153
Activest Wealth Management 0% 2 0% 0% $5
OSAIC HOLDINGS, INC. 0% 0 -100% $0
XTX Topco Ltd 0% 0 -100% $0
Rangeley Capital, LLC 0% 0 -100% $0

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
10
Headline period
Q2 2026
Rows shown
1-10 of 10
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 258 $660 $2.53 2
2026 Q2 1,105,562 $2,907,476 +$2,041,251 $2.63 22
2026 Q1 339,203 $654,660 -$727,610 $1.93 18
2025 Q4 706,945 $1,392,679 +$165,896 $1.97 19
2025 Q3 616,169 $1,714,712 -$910,084 $2.78 17
2025 Q2 931,843 $2,683,707 -$1,054,952 $2.88 16
2025 Q1 1,285,403 $3,869,063 +$78,079 $3.01 18
2024 Q4 1,259,459 $4,164,082 +$76,847 $3.30 16
2024 Q3 1,213,569 $4,441,661 +$905,961 $3.66 18
2024 Q2 966,044 $4,057,360 +$4,057,360 $4.20 15
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .